In the last trading session, 1.45 million Marinus Pharmaceuticals Inc (NASDAQ:MRNS) shares changed hands as the company’s beta touched 1.27. With the company’s per share price at $0.33 changed hands at -$0.02 or -3.10% during last session, the market valuation stood at $17.74M. MRNS’s last price was a discount, traded about -3312.12% off its 52-week high of $11.26. The share price had its 52-week low at $0.26, which suggests the last value was 21.21% up since then. When we look at Marinus Pharmaceuticals Inc’s average trading volume, we note the 10-day average is 3.19 million shares, with the 3-month average coming to 2.34 million.
Analysts gave the Marinus Pharmaceuticals Inc (MRNS) stock a consensus recommendation rating of Buy, calculated at a mean rating of 2.40. If we narrow down to specifics, the data shows that 0 out of 2 analysts rate the stock as a Sell, with a further 0 assigning it an Overweight rating. Of the remaining, 1 recommended MRNS as a Hold, 1 felt it is a Buy and 0 rated the stock as Underweight. Marinus Pharmaceuticals Inc’s EPS for the current quarter is expected to be -0.41.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
Marinus Pharmaceuticals Inc (NASDAQ:MRNS) trade information
Instantly MRNS was in red as seen at the end of in last trading. With action 0.63%, the performance over the past five days has been green. The company’s shares are showing year-to-date downside of -96.92%, with the 5-day performance at 0.63% in the green. However, in the 30-day time frame, Marinus Pharmaceuticals Inc (NASDAQ:MRNS) is -80.87% down. Looking at the short shares, we see there were 3.49 million shares sold at short interest cover period of 4.89 days.
The consensus price target for the stock as assigned by Wall Street analysts is 3, meaning bulls need an upside of 89.0% from its current market value. According to analyst projections, MRNS’s forecast low is 2 with 6 as the target high. To hit the forecast high, the stock’s price needs a -1718.18% plunge from its current level, while the stock would need to soar -506.06% for it to hit the projected low.
Marinus Pharmaceuticals Inc (MRNS) estimates and forecasts
Data shows that the Marinus Pharmaceuticals Inc share is performing relatively much better than most of its peers within the same industry. As can be gleaned from the statistics, the company’s share value shot -75.21% over the past 6 months, a 22.81% in annual growth rate that is considerably higher than the industry average of 18.20%. Year-over-year growth is forecast to reach 18.40% up from the last financial year.
Consensus estimates given by 10 financial analysts project the company’s revenue in the current quarter to hit an average of 9.42M. 10 analysts are of the opinion that Marinus Pharmaceuticals Inc’s revenue for the current quarter will be 11.53M. The company’s revenue for the corresponding quarters a year ago was 7.34M and 7.19M respectively. According to analysts, the company will likely register a growth in its current quarter sales, forecast at 28.40%. The estimates for the next quarter sales put growth at 60.40%.
Looking at the company’s year-on-year earnings, data shows that the past 5-year has an earnings growth rate of 6.04%. The 2024 estimates are for Marinus Pharmaceuticals Inc earnings to increase by 26.21%, but the outlook for the next 5-year period is at 20.00% per year.
MRNS Dividends
Marinus Pharmaceuticals Inc is expected to release its next quarterly earnings report in December.
Marinus Pharmaceuticals Inc (NASDAQ:MRNS)’s Major holders
If we look at who the major shareholders are, we find that insiders hold 10.94% of Marinus Pharmaceuticals Inc shares while 82.90% of the shares are in the hands of institutional holders. The share float percentage for the stock currently stands at 93.09%. There are 82.90% institutions holding the Marinus Pharmaceuticals Inc stock share, with TANG CAPITAL MANAGEMENT LLC the top institutional holder. As of 2024-06-30, the company held 8.443% of the shares, roughly 4.8 million MRNS shares worth $5.62 million.
SOFINNOVA INVESTMENTS, INC. holds the second largest percentage of outstanding shares, with 7.3025% or 4.15 million shares worth $4.86 million as of 2024-06-30.
